1257848-48-8 Usage
General Description
"(R)-N-Boc-Morpholine-2-acetic acid" is a specialized chemical compound that belongs to the group of organic compounds known as morpholines. The 'Boc' in its name refers to a protective group used in chemistry called 'tert-butyloxycarbonyl' which prevents unwanted reactions from occurring in specific parts of a molecule during a synthesis process. (R)-N-Boc-Morpholine-2-acetic acid is commonly used in scientific research settings, particularly in the fields of organic and medicinal chemistry, for the synthesis of various pharmaceuticals and other organic compounds. Due to its specific structure and protective 'Boc' group, it exhibits unique chemical behaviors which makes it a valuable tool for researchers. It should be handled with caution due to its sensitive characteristics features.
Check Digit Verification of cas no
The CAS Registry Mumber 1257848-48-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,7,8,4 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1257848-48:
(9*1)+(8*2)+(7*5)+(6*7)+(5*8)+(4*4)+(3*8)+(2*4)+(1*8)=198
198 % 10 = 8
So 1257848-48-8 is a valid CAS Registry Number.
1257848-48-8Relevant articles and documents
Novel anticancer compound and usage thereof
-
Paragraph 0032; 0033; 0046; 0047; 0048; 0049, (2019/06/27)
The invention provides a novel anticancer compound. The novel anticancer compound is a compound shown in chemical formula 1 in the description or pharmaceutically acceptable salt of the compound, andthe compound and the salt are active ingredients of a pharmaceutical composition for inhibiting the activity of hepatocyte growth factor receptor (c-Met) tyrosine kinase and pharmaceutical compositionfor preventing or curing excessive or abnormal proliferative diseases. The compound effectively inhibits the activity of the hepatocyte growth factor receptor tyrosine kinase, thereby being suitablefor treating the diseases with the characteristics of excessive or abnormal cell proliferation.
